How to diagnose COVID-19 in family practice? Usability of complete blood count as a COVID-19 diagnostic tool: a cross-sectional study in Turkey

Author:

Bayraktar MustafaORCID,Tekin Erdal,Kocak Mehmet Nuri

Abstract

ObjectiveCOVID-19 is currently diagnosed in hospital settings. An easy and practical diagnosis of COVID-19 is needed in primary care. For this purpose, the usability of complete blood count in the diagnosis of COVID-19 was investigated.DesignRetrospective, cross-sectional study.SettingSingle-centre study in a tertiary university hospital in Erzurum, Turkey.ParticipantsBetween March 2020 and February 2021, patients aged 18–70 years who applied to the hospital and underwent both complete blood count and reverse-transcription-PCR tests for COVID-19 were included and compared. Conditions affecting the test parameters (oncological–haematological conditions, chronic diseases, drug usage) were excluded.Outcome MeasureThe complete blood count and COVID-19 results of eligible patients identified using diagnostic codes [U07.3 (COVID–19) or Z03.8 (observation for other suspected diseases and conditions)] were investigated.ResultsOf the 978 patients included, 39.4% (n=385) were positive for COVID-19 and 60.6% (n=593) were negative. The mean age was 41.5±14.5 years, and 53.9% (n=527) were male. COVID-19-positive patients were found to have significantly lower leucocyte, neutrophil, lymphocyte, monocyte, basophil, platelet and immature granulocyte (IG) values (p<0.001). Neutrophil/lymphocyte, neutrophil/monocyte and IG/lymphocyte ratios were also found to be significantly decreased (p<0.001). With logistic regression analysis, low lymphocyte count (OR 0.695; 95% CI 0.597 to 0.809) and low red cell distribution width-coefficient of variation (RDW-CV) (OR 0.887; 95% CI 0.818 to 0.962) were significantly associated with COVID-19 positivity. In receiver operating characteristic analysis, the cut-off values of lymphocyte and RDW-CV were 0.745 and 12.35, respectively.ConclusionAlthough our study was designed retrospectively and reflects regional data, it is important to determine that low lymphocyte count and RDW-CV can be used in the diagnosis of COVID-19 in primary care.

Publisher

BMJ

Subject

General Medicine

Reference21 articles.

1. WHO timeline: WHO’s COVID–19 response: world health organization [15.11.2022]. n.d. Available: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline#event-69

2. WHO coronavirus disease (COVID–19) dashboard: world health organization [15.11.2022]. n.d. Available: https://covid19.who.int/

3. Diagnostic testing for SARS-cov-2: world health organization [15.11.2022]. n.d. Available: https://www.who.int/publications/i/item/diagnostic-testing-for-sars-cov-2

4. Sayed AA . The cost-effectiveness of requesting a complete blood count (CBC) in the management of COVID-19 in saudi arabia. Healthcare (Basel) 2022;10:1780. doi:10.3390/healthcare10091780 Available: https://doi.org/10.3390/healthcare10091780

5. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis;Lagunas-Rangel;J Med Virol,2020

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3